STX Insider Trading

Insider Ownership Percentage: 62.16%
Insider Buying (Last 12 Months): GBX 0
Insider Selling (Last 12 Months): GBX 0

Shield Therapeutics Insider Trading History Chart

This chart shows the insider buying and selling history at Shield Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Shield Therapeutics Share Price & Price History

Current Price: GBX 2.71
Price Change: Price Decrease of -0.268 (-8.99%)
As of 11/4/2024 12:13 PM ET

This chart shows the closing price history over time for STX up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365

Shield Therapeutics Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/23/2022Greg MadisonInsiderSell466,395GBX 7£32,647.65
See Full Table

SEC Filings (Institutional Ownership Changes) for Shield Therapeutics (LON:STX)

11.92% of Shield Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Shield Therapeutics logo
Shield Therapeutics plc, a specialty pharmaceutical company, focuses on commercialization of pharmaceuticals to treat unmet medical needs. Its lead product is Accrufer/Feraccru, a non-salt based oral therapy for adults to treat the iron deficiency with or without anemia. Shield Therapeutics plc was founded in 2008 and is based in Gateshead, the United Kingdom.
Read More on Shield Therapeutics

Today's Range

Now: GBX 2.71
Low: 2.70
High: 2.90

50 Day Range

MA: GBX 4.27
Low: 2.98
High: 5.34

52 Week Range

Now: GBX 2.71
Low: 1.06
High: 7.80

Volume

1,493,523 shs

Average Volume

4,681,889 shs

Market Capitalization

£21.21 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.42

Who are the company insiders with the largest holdings of Shield Therapeutics?

Shield Therapeutics' top insider shareholders include:
  1. Greg Madison (Insider)
Learn More about top insider investors at Shield Therapeutics.